Brexit – Indian Pharma’s Diversified Play A Buffer?

Indian markets slumped on June 24 after the UK voted to exit the EU, though industry experts had mixed views on how things may pan out for Indian drug firms with an exposure in Britain or Europe as a whole. Most concurred only that there would be turbulence in the currency markets in the short term.

More from Focus On Asia

More from Scrip